Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Oral Oncol ; 98: 48-52, 2019 11.
Article in English | MEDLINE | ID: mdl-31539757

ABSTRACT

BACKGROUND: Induction chemotherapy in locally-advanced head and neck squamous cell carcinoma (LAHNSCC) patients is potentially associated to serious adverse events. Biomarkers associated with toxicity could tailor its indication. This study evaluated the association between single-nucleotide polymorphisms (SNPs) in metabolic genes and toxicity to induction chemotherapy. METHODS: 59 LAHNSCC phase II clinical trial patients (NCT00959387) were assessed regarding 47 metabolic genes (366 SNPs). Toxicities were graded (CTCAE 3.0) and statistical analysis was performed. RESULTS: The SNPs rs8187710 (ABCC2) and rs1801131 (MTHFR) were associated to increased risk of gastrointestinal toxicity, whereas the SNPs rs3788007 (ABCG1) and rs4148943 (CHST3) were associated to decreased risk. Two other SNPs, rs2301159 (SLC10A2) and rs2470890 (CYP1A2), were associated with increased risk of hematological toxicity. Nevertheless, these SNPs did not remain significant after adjusting for multiple comparisons. CONCLUSIONS: This study could not demonstrate relationship between SNPs and toxicity to induction chemotherapy in LAHNSCC patients. The small number of patients may have affected the results.


Subject(s)
Antineoplastic Agents/adverse effects , Cisplatin/adverse effects , Head and Neck Neoplasms/genetics , Paclitaxel/adverse effects , Pharmacogenomic Variants , Polymorphism, Single Nucleotide , Alleles , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cisplatin/therapeutic use , Female , Genotype , Head and Neck Neoplasms/diagnosis , Head and Neck Neoplasms/drug therapy , Humans , Induction Chemotherapy , Male , Multidrug Resistance-Associated Protein 2 , Odds Ratio , Paclitaxel/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...